PEG-IFN VS ROFERON A IN NONCIRRHOTIC HEPATITIS C

PEG-IFN 与 Roferon A 在非硬化性丙型肝炎中的比较

• 批准号: 6307387
• 负责人: PAUL J POCKROS
• 金额: $ 2.74万
• 依托单位: SCRIPPS RESEARCH INSTITUTE, THE
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-12-01 至 2001-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6307387
• 关键词: clinical research; drug screening /evaluation; hepatitis C; human subject; human therapy evaluation; immunotherapy; interferon alpha; liver disorder chemotherapy; polyethylene glycols

This open-label randomized study compares the safety and efficacy of four ascending doses of PEG-interferon a-2a given once a week with a standard thrice weekly regimen of Roferon-A in non-cirrhotic patients with chronic hepatitis C. Endpoints for evaluation of efficacy will be normalization of ALT and disappearance of detectable HCV RNA from the serum.

这项开放标签随机研究比较了4种递增剂量的PEG-干扰素a-2a每周一次与标准的Roferon-A每周三次治疗方案在慢性丙型肝炎非肝硬化患者中的安全性和有效性。 疗效评价的终点是ALT正常化和血清中可检测到的HCV RNA消失。